10 posts from ASCO GU 2024 by Yüksel Ürün
Yüksel Ürün, Professor of Medical Oncology at Ankara University, has recapped ASCO GU highlights on X. Here we feature 10 of his posts on OncoDaily.
1. “Derya Tilki’s excellent presentation on “Setting the Stage: Biochemical Recurrence After Local Treatment for Prostate Cancer”
Defining biochemical recurrence in prostate cancer is crucial for patient outcomes.”
Source: Yüksel Ürün/X
2. “Delving into the ENZAMET trial: Radiographic progression in mHSPC may occur without PSA elevation, challenging conventional monitoring methods. The study underscores the complexity of disease progression.”
Source: Yüksel Ürün/X
3. “Karen E. Hoffman, MD from MD Anderson Cancer Center presents FORMULA-509 trial HRQoL:
Adding AAP/Apa to salvage radiation + GnRH Agonist shows no difference in PRO of QoL vs bicalutamide alone!”
Source: Yüksel Ürün/X
4. “Diving into mCRPC treatments with Ravindran Kanesvaran stellar talk on the synergy of AR targeting + PARP inhibition. The data’s in this combo could lead the way in efficacy.
Greater benefit in biomarker-selected patients.”
5. “Christophe Hennequin, MD from GETUG:
New GETUG-AFU 18 study reveals: Higher dose RT + long-term ADT boosts survival in high-risk prostate cancer without added long-term toxicity.”
Source: Yüksel Ürün/X
6. “Zachery R. Reichert MD, University of Michigan Medical School
Why do ARSIs lose their edge in cancer treatment?
It’s often due to mutations or increased numbers of androgen receptors (63%), cancer’s own androgen production, or changes in the androgen receptor (ARV7, 30+%). Sometimes, cancer outsmarts one path only to get blocked by another.”
Source: Yüksel Ürün/X
7. “Excellent discussion by Neha Vapiwala starting with the etymology of synergy:
The word ‘synergy’ comes from the Greek word ‘synergos,’ which means ‘working together.’ The prefix ‘syn-‘ means ‘together,’ and ‘ergos’ means ‘work’.
Let’s have more stronger synergy in Cancer Research.”
Source: Yüksel Ürün/X
8. BRCAAway trial! Phase 2 results show a promising path for mCRPC patients with BRCA/ATM mutations. Abiraterone + Olaparib combo leads to better survival outcomes. By Maha Hussain.
Source: Yüksel Ürün/X
9. “Alan H. Bryce, how to choose between Ra223 or Lu-177?
Today’s decision affects tomorrow’s practice too!
Navigating advanced prostate cancer treatment with PSMA-targeting and Radium-223. For those on double or triplet therapy facing resistance, it’s all about precision and protection.”
Source: Yüksel Ürün/X
10. “Neeraj Agarwal, excellent presentation CONTACT-2
– Cabo-atezo better than NHT
– Role of adding atezo?
– Control arm? AR switch?”
Source: Yüksel Ürün/X
